Back to Research Hub
Madrigal Pharmaceuticals, Inc.
MDGL
$476.89+9.61 (+2.06%)
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases.
StreetsValue research for Madrigal Pharmaceuticals, Inc. (MDGL)
Members get the full report for Madrigal Pharmaceuticals, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.